These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1507517)

  • 21. Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction.
    Hashimoto H; Satoh N; Nakashima M
    J Cardiovasc Pharmacol; 1992 Mar; 19(3):417-24. PubMed ID: 1378123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demonstration of proarrhythmic activity with the class IC antiarrhythmic agent encainide in a canine model of previous myocardial infarction.
    Wallace AA; Stupienski RF; Kothstein T; Gehret JR; Lynch JJ
    J Cardiovasc Pharmacol; 1993 Mar; 21(3):397-404. PubMed ID: 7681500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model.
    Uprichard AC; Harron DW
    Br J Pharmacol; 1989 Jan; 96(1):220-6. PubMed ID: 2924074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes.
    Nakaya H; Tohse N; Takeda Y; Kanno M
    Br J Pharmacol; 1993 May; 109(1):157-63. PubMed ID: 7684298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
    Drexler AP; Micklas JM; Brooks RR
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidysrhythmic actions of meobentine sulfate.
    Zimmerman JM; Patterson E; Pitt B; Lucchesi B
    Am Heart J; 1984 Jun; 107(6):1117-24. PubMed ID: 6720538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of pirmenol on electrical induction of sustained ventricular tachycardia in a seven-day-old canine myocardial infarction.
    Nitta J; Nogami A; Aonuma K; Akimoto H; Chung YH; Takahashi A; Iesaka Y; Marumo F; Hiraoka M
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):54-60. PubMed ID: 1708056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.
    Naitoh N; Taneda K; Tagawa M; Furushima H; Yamaura M; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):297-305. PubMed ID: 9711181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
    Lee SD; Newman D; Ham M; Dorian P
    J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide.
    Buchanan LV; Kabell G; Turcotte UM; Brunden MN; Gibson JK
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):256-63. PubMed ID: 1376795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias.
    Naitoh N; Tagawa M; Yamaura M; Taneda K; Furushima H; Aizawa Y
    Jpn Heart J; 1998 Jul; 39(4):457-67. PubMed ID: 9810296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiarrhythmic effects of bisaramil in canine models of ventricular arrhythmia.
    Haruno A; Hashimoto K
    Eur J Pharmacol; 1993 Mar; 233(1):1-6. PubMed ID: 8472737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meobentine sulfate: antiarrhythmic and electrophysiologic effects assessed by programmed electrical stimulation and ambulatory monitoring in patients with complex ventricular tachyarrhythmia. Report of a multicenter evaluation.
    Anderson JL; Reid PR; Platia EV; Akhtar M; Ruskin JN; Schaal SF; Jueng P; Long RA; Wenger TL
    Am Heart J; 1985 Oct; 110(4):774-84. PubMed ID: 3901715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiarrhythmic and electrophysiologic effects of bepridil in chronically infarcted conscious dogs.
    Lynch JJ; Montgomery DG; Ventura A; Lucchesi BR
    J Pharmacol Exp Ther; 1985 Jul; 234(1):72-80. PubMed ID: 3874285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction.
    Koch KT; Düren DR; van Zwieten PA
    Cardiovasc Drugs Ther; 1995 Jun; 9(3):437-43. PubMed ID: 8527354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death.
    Lynch JJ; Coskey LA; Montgomery DG; Lucchesi BR
    Am Heart J; 1985 May; 109(5 Pt 1):949-58. PubMed ID: 3993529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo antiarrhythmic profile of AP-792 assessed in different canine arrhythmia models.
    Takahara A; Hirasawa A; Dohmoto H; Shoji M; Yoshimoto R; Sugiyama A; Hashimoto K
    Jpn J Pharmacol; 2001 Sep; 87(1):21-6. PubMed ID: 11676194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiarrhythmic and electrophysiologic actions of clofilium in experimental canine models.
    Kopia GA; Eller BT; Patterson E; Shea MJ; Lucchesi BR
    Eur J Pharmacol; 1985 Oct; 116(1-2):49-61. PubMed ID: 4054216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic actions of tocainide in canine models of previous myocardial infarction.
    Wallace AA; Stupienski RF; Heaney LA; Gehret JR; Lynch JJ
    Am Heart J; 1991 May; 121(5):1413-21. PubMed ID: 1708198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiarrhythmic vs. antifibrillatory activity of the basic diphenylhydantoin derivative 3-[3-(4-phenyl-1-piperidyl)propyl]-5-(4-methoxyphenyl)-5-phenylhydantoin hydrochloride.
    Lynch J; Montgomery D; Ventura A; Wilber D; Lucchesi BR
    Arzneimittelforschung; 1986 Mar; 36(3):475-81. PubMed ID: 3707667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.